Abstract Details

Title Utility of D-dimer for oncologic disease suspicion in patients with cryptogenic ischemic stroke.

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-033

Objective To compare DD values in patients with non-determined ischemic or cryptogenic stroke (TOAST-V), with active solid organ cancer (AC), compared to those with non-AC.

Background Ischemic stroke and cancer are among the leading causes of death globally. There are reports showing the presence of elevated D-dimer (DD) in patients with stroke and concomitant neoplasm, being this proposed as a possible new biomarker.

Design/Methods Retrospectively collected data of admitted patients with first time acute TOAST-V ischemic stroke from June 2012 to June 2017. We searched for concomitant AC and DD values.

Results Sixty-seven cases were reviewed, 55 TOAST-V ischemic stroke, non-AC and 12 patients with ischemic stroke and AC. The mean age was 65.81 +/- 15.18 years and 40.3% were women. Of the patients with cancer, the most frequent sites were: lung (25%) and breast (15%). DD values were significantly higher in patients with AC compared to patients without AC (4.45 +/- 3.07 vs. 1.28 +/- 2.01μg / ml, p <0.001). DD> 1.5μg / ml was significantly more frequent in the AC group (91.67% vs. 27.27%, p <0.001). C-reactive protein (CRP) values were significantly higher in patients with AC (57.66 +/- 52.36 vs. 7.33 +/- 13.54 mg / l p: 0.0013). The mean follow-up of cryptogenic stroke patients was 18.55 +/- 16.59 months.

Conclusions Our results support the idea of using DD as a biomarker in any ischemic stroke without clear etiology in order to consider cancer as a possible cause and further search for this condition. Alternatively, CRP may be equally useful for this purpose. This allows optimizing the patient's study.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Gustavo Da Prat de Magahlaes	Gustavo Da Prat de Magahlaes has nothing to disclose.
	No disclosure on file
Gabriel Martino	No disclosure on file
Maria Pilar Sanchez de Paz	No disclosure on file
Emilia M. Gatto, MD, FAAN (INEBA)	Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for Bago Argentina. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bago. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Janssen. Dr. Gatto has received research support from Roche. The institution of Dr. Gatto has received research support from CHDI.
Gabriel Persi (Sanatorio de la Trinidad Mitre)	Gabriel Persi has nothing to disclose.

��ɫ��

��ɫ��